Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3826 - Pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC): Further evaluation of efficacy including tumor growth rates (GR) analysis. H&N Unicancer Group PACSA trial with the REFCOR


09 Oct 2016


Poster display


Joël Guigay


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


J. Guigay1, F. Bidault2, J. Fayette3, C. Even4, D. Cupissol5, F. Rolland6, F. Peyrade1, B. Laguerre7, C. Le Tourneau8, S. Zanetta9, L. Bozec Le Moal10, C. Borel11, L. Digue12, J. Delaye13, S. Diffetocq2, V. Costes14, A. Auperin15, L. Faivre15

Author affiliations

  • 1 Medical Oncology Departement, Centre Antoine Lacassagne, 06100 - Nice/FR
  • 2 Medical Imaging, Institut Gustave Roussy, Villejuif/FR
  • 3 Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 4 Department Of Head And Neck Cancer, Institut Gustave Roussy, 94805 Villejuif Cedex - Villejuif/FR
  • 5 Medicine, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 6 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - St. Herblain/FR
  • 7 Medical Oncology, Centre Eugene - Marquis, Rennes/FR
  • 8 Dept Of Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 9 Oncology Department, Centre Georges-François Leclerc (Dijon), 21000 - Dijon/FR
  • 10 Hôpital René Huguenin, Dept Of Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 11 Medical Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg/FR
  • 12 Department Of Medical Oncology, CHU Bordeaux Hopital St. André, Bordeaux/FR
  • 13 H&n Group, UNICANCER, Paris/FR
  • 14 Pathology, CHU Hôpital Gui de Chauliac, Montpellier/FR
  • 15 Biostatitics And Epidemiology, Institut Gustave Roussy, Villejuif/FR


Abstract 3826


SGC of head and neck (SGCHN) are rare tumors including adenoid cystic carcinoma (ACC) and non-ACC, with no standard treatment for R/M patients (pts). Pazopanib (Pb) is an oral inhibitor of VEGFR, PDGFR and KIT. We conducted a phase II trial to assess Pb efficacy in SGCHN, and present here results of the ancillary GR study.


Pts with confirmed progressive R/M SGCHN received Pb 800 mg daily until progression (PD). Primary endpoint was 6-mo PFS rate, with inacceptable and promising rates of 20% and 40%. Tumor volumes were assessed with a medical imaging workstation (Advantage Workstation, GE Healthcare) Assuming exponential growth, GR was defined as log10(Vt/V0)/dt, where V0 and Vt are tumour volumes at time 0 and t and dt the time in months between time 0 and t. Two time periods: pretrial period, from 3-6 mo before inclusion to inclusion (GRpre) and trial period, from inclusion to 3 mo later (GRpost). GR variation was defined as the difference GRpost minus GRpre., a negative difference means a GR break (GRpost 


From 2013 to 2015, 72 pts were enrolled: 49 ACC and 20 non-ACC (3 ineligible excluded), M:F = 32:37, median age 59 yrs (range 27-84), PS 0-1 = 42:27. Pb tolerance was as expected. Among 63 pts (45 ACC, 18 non-ACC) evaluable for efficacy (6 non progressive excluded), 6-mo PFS rate was 47% (95%CI = 36;60) with 30 pts without PD at 6 mo, median PFS was 5.9 mo. Median OS was 17 mo. The 6-mo PFS met the criteria for efficacy conclusion of the trial. GR study was performed among 31 patients (24 ACC, 7 non-ACC). 6-mo PFS was 61% [IC95%:43;76] with 19 pts without PD at 6 mo. Median PFS was 8.2 mo. GR variation analysis showed a significant GR break 3 mo after Pb start (median -0.06 (range -0.37; + 0.10) p 


There is a significant decrease in GR between evaluations done before inclusion and 3 months after Pb start, i.e. a break in tumor growth rate, in agreement with the PFS based conclusion of promising efficacy of Pb in R/M SGCHN.

Clinical trial identification


Legal entity responsible for the study



UNICANCER Ligue Contre le Cancer GSK/Novartis


J. Guigay: Advisory Boards: BMS, Merck Research Grants: BMS, Chugai, GSK, Merck. J. Fayette: Leadership: Glycotope Gmbh. C. Even: Advisory role: MSD Travel expenses: Merck, Astra Zeneca. B. Laguerre: Honoraria and travel expenses: Novartis. C. Le Tourneau: Honoraria: Novartis, BMS, Debiopharm, MERCK, Caris. L. Digue: Travel expenses: MSD. A. Auperin: Travel expenses: Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings